What if we treated the symptoms instead of chasing the cause?
For generations, Alzheimer's research has pursued the disease at its roots — chasing plaques and tangles in hopes of a cure. A systematic review of 19 studies now invites a quieter but meaningful question: what if relieving the suffering of the present moment is itself a worthy goal? Researchers have found that drugs designed for ADHD, which act on the brain's noradrenergic system, can modestly improve cognition and reduce the emotional emptiness known as apathy in Alzheimer's patients — a reminder that in the absence of a cure, the quality of a life still lived deserves its own science.
- Decades of Alzheimer's research targeting amyloid plaques and tau tangles have yet to yield a cure, leaving millions of patients without meaningful symptom relief.
- The locus coeruleus — the brain's first casualty in Alzheimer's — governs attention, memory, and learning, and its collapse triggers a cascade of inflammation that accelerates the disease.
- A pooled analysis of over 1,800 patients found ADHD medications improved overall cognition and reduced apathy, but left memory deficits and agitation largely untouched.
- Methylphenidate emerged as the most promising candidate, with a six-month trial showing real gains against apathy — the hollow indifference that quietly devastates quality of life.
- Serious risks remain: heart complications, addiction potential, and one drug in the review was linked to increased early death, demanding rigorous controlled trials before any clinical pivot.
For decades, Alzheimer's research has followed a single ambition: find the disease's biological source and eliminate it. But a growing chorus of scientists is asking whether treating the symptoms themselves — the cognitive fog, the emotional flatness — might be equally worth pursuing.
A systematic review drawing on 19 studies and more than 1,800 patients suggests this reframing has merit. Drugs commonly prescribed for ADHD, which act on the brain's noradrenergic system, were found to improve certain cognitive functions and reduce apathy in Alzheimer's patients. The finding is modest, but it points toward a broader toolkit at a moment when the dominant research strategy has yet to deliver.
The noradrenergic system originates in the locus coeruleus, a brainstem cluster that governs memory, attention, and learning. It is also the first brain region to accumulate the tau tangles that define Alzheimer's pathology. As those tangles spread, they impair the system's ability to regulate neuroinflammation — accelerating the disease's progression. The same system is implicated in depression, anxiety, and ADHD, which is why shared medications exist across these conditions — and why people with those conditions face elevated Alzheimer's risk.
The review found noradrenergic drugs improved general cognition but not specific memory functions — word recall, spatial navigation, following instructions. They also failed to reduce agitation. Their clearest benefit was against apathy, a condition that drains motivation, accelerates decline, and hollows out daily life. Among the drugs studied, methylphenidate showed the most consistent promise for apathy reduction.
The caveats are real. This was a review, not a controlled trial, and the included studies varied widely. Noradrenergic drugs carry risks — cardiac effects, addiction potential, and in misuse cases, psychiatric symptoms. One drug, mirtazapine, was associated with increased early mortality. The Cardiff University researchers are measured in their conclusions: the evidence warrants further investigation, particularly rigorous trials of methylphenidate, but the path forward remains genuinely uncertain.
For decades, the hunt for an Alzheimer's cure has led researchers down one particular path: find the disease's root cause and eliminate it. But a growing number of scientists are asking a different question. What if, instead of chasing the underlying biology, we treated the symptoms themselves—the cognitive fog, the emotional flatness, the slow erosion of function that makes the disease so devastating to live with?
A systematic review of 19 studies, pooling data from over 1,800 patients, suggests this reframing might be worth pursuing. Researchers found that drugs normally prescribed for ADHD—medications that work on a brain system called the noradrenergic network—can improve certain cognitive abilities and reduce apathy in people with Alzheimer's disease. The finding is modest but intriguing: a shift in strategy that acknowledges what decades of chasing amyloid plaques and tau tangles has not yet delivered.
The noradrenergic system is a small but consequential part of the brain. It originates in a region called the locus coeruleus, a cluster of cells in the brainstem that influences memory, attention, and learning. The system runs on a neurotransmitter called noradrenaline, the same chemical that kicks in during moments of stress or danger—the body's fight-or-flight response. What makes this system relevant to Alzheimer's is that the locus coeruleus is the first brain region to show the disease's hallmark damage: tangles of a protein called tau. As these tangles accumulate, they strangle the noradrenergic system's ability to keep neurons functioning. The system also helps regulate the brain's immune response, so when it fails, inflammation spreads—another signature of Alzheimer's pathology.
The connection runs deeper still. Depression, anxiety, and ADHD all involve problems with the noradrenergic system, which is why the same drugs treat all three conditions. And here's what compounds the tragedy: people with these mental health conditions face higher risk of developing Alzheimer's. Worse, depression and anxiety often appear years before memory loss sets in, and their presence in Alzheimer's patients is linked to earlier death.
When researchers examined the 19 studies, they found that noradrenergic drugs improved overall thinking and cognition in most cases. But they did not improve specific memory functions—the ability to recall words or events, to follow instructions, to navigate space. They also did not reduce agitation. What they did improve, consistently, was apathy: that hollow indifference that can be as disabling as memory loss itself. Apathy drains motivation, accelerates cognitive decline, and devastates quality of life. Among the drugs tested, methylphenidate—known as Ritalin—emerged as the most effective for reducing apathy. A short-term clinical trial using it for six months showed promise.
But the caveats matter. This was a systematic review, not a randomized controlled trial, the gold standard for proving a drug works. The studies included varied wildly in design and results. And noradrenergic drugs carry real risks: heart problems, addiction potential, and in cases of misuse, psychiatric symptoms including hallucinations and paranoia. One drug in the review, the antidepressant mirtazapine, not only failed to improve apathy but was associated with increased risk of early death.
The researchers, from Cardiff University, are careful not to oversell their findings. What the review does suggest is that the field might benefit from a pivot—not abandoning the search for root causes, but broadening the toolkit to include treatments that address the systems Alzheimer's damages. Methylphenidate warrants further investigation, but only if rigorous trials can prove the benefits genuinely outweigh the harms. For now, the door is open, but the path forward remains uncertain.
Citações Notáveis
Instead of focusing only on potential causes, research could benefit from including treatments that target the systems involved in different Alzheimer's symptoms.— Eleftheria Kodosaki and Katie Sedgwick, Cardiff University
A Conversa do Hearth Outra perspectiva sobre a história
Why would a drug for ADHD help with Alzheimer's? They seem like completely different diseases.
They're different diseases, but they both involve the same brain system—the one that handles attention, motivation, and how your neurons stay healthy. In Alzheimer's, that system gets damaged early. ADHD drugs were designed to fix problems in that same system, so it makes sense to ask whether they might help repair some of the damage.
The review found improvements in thinking overall, but not in memory. That seems like a missed opportunity.
It does, but apathy might actually be the bigger problem. You can lose some memory and still function if you're motivated. But apathy—that hollow indifference—it paralyzes people. They stop trying, stop engaging. It accelerates everything else. If a drug can restore that drive, it changes the texture of someone's life.
But the article mentions serious side effects—heart problems, addiction, even psychosis. How do you weigh that against apathy?
That's the hard question. You don't. Not yet. That's why they need proper clinical trials. Right now we have hints that it might work, but we don't know if those hints are strong enough to justify the risks. One drug in the review actually made things worse.
What's the bigger shift here? Why does this matter beyond just finding another treatment?
Because for decades, researchers have been hunting for the root cause—the thing that starts Alzheimer's. This suggests maybe we should also ask: what can we actually treat right now, even if we don't fully understand the cause? It's a different kind of medicine. Symptom-focused instead of cause-focused.
And that works?
Sometimes. Not always. But for people living with the disease, sometimes is better than nothing.